Professor Daniel Heng shares his thoughts on the developments of the last few years in the field of mRCC.

Video: https://medicaldigest.org/scientific-contents/interview:treatment-mrcc-real-world-settings

Professor Krishnansu Sujata Tewari explains the results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab vedotin demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy. These are the late-breaking results presented at ESMO 2023 congress.

Video: https://medicaldigest.org/scientific-contents/interview:antibody-drug-conjugate-boosts-survival-recurrentmetastatic-cervical-cancer

Professor Ignace B. Vergote explains the results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab vedotin demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy. These are the late-breaking results presented at ESMO 2023 congress.

Video: https://medicaldigest.org/scientific-contents/interview:data-shows-survival-benefits-tisotumab-vedotin-cervical-cancer

Professor Paweł Sobczuk shares his thoughts on five interesting studies presented during #ESMO23. These groundbreaking studies is form different tumor types like breast cancer, lung cancer and prostate cancer.

Video: https://medicaldigest.org/scientific-contents/interview:late-breaking-studies-esmo-2023

Professor Jeffrey Weber shares his thoughts on the novel techniques in the field of melanoma. Like 5-Year Efficacy and Biomarker Results from CheckMate 238 and KEYNOTE-942, a combination of pembrolizumab plus a novel mRNA-based vaccine based on personalised neoantigens from patients with high-risk resected melanoma.

Video: https://medicaldigest.org/scientific-contents/interview:keynote-942-mrna-based-vaccine-and-novel-techniques-field-melanoma

Professor Filippo Pietrantonio discusses the influence of primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab on KRAS G12C-mutated metastatic colorectal cancer.

Video: https://medicaldigest.org/scientific-contents/interview:targeted-combination-wins-kras-positive-metastatic-colorectal-cancer

Professor Krishnansu Sujata Tewari explains the results from he INTERLACE phase 3 trial, assessed whether a short course of induction chemotherapy prior to chemoradiation could reduce the rate of relapse and death among patients with locally advanced cervical cancer. As part of an analysis of clinical data, the preliminary results will be presented at the European Society for Medical Oncology congress 2023.

Video: https://medicaldigest.org/scientific-contents/interview:better-use-existing-drugs-increases-cervical-cancer-survival-and-reduces-recurrence

Professor Mary McCormack explains the results from the GCIG INTERLACE trial presented in a Presidential Symposium at the ESMO Congress 2023. Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease.

Video: https://medicaldigest.org/scientific-contents/interview:induction-chemotherapy-added-chemoradiation-improves-pfs-and-os-advanced-cervical-cancer

Professor Clara Montagut Viladot discusses the primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer.

Video: https://medicaldigest.org/scientific-contents/interview:codebreak-300-trial-kras-g12c-mutated-mcrc

Professor Michiel van der Heijden presented the results of CheckMate 901, a phase III trial evaluating the combination of nivolumab plus gemcitabine/cisplatin versus gemcitabine/cisplatin alone for patients with previously untreated unresectable or metastatic urothelial carcinoma. He shares details on the design of the trial and the late-breaking results that he presented at ESMO 2023.

Video: https://medicaldigest.org/scientific-contents/interview:survival-improved-nivolumab-plus-chemo-urothelial-carcinoma